On Monday, Editas Medicine Inc (NASDAQ: EDIT) opened lower -9.30% from the last session, before settling in for the closing price of $1.72. Price fluctuations for EDIT have ranged from $1.12 to $9.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 96.99% over the last five years. Company’s average yearly earnings per share was noted 49.03% at the time writing. With a float of $82.23 million, this company’s outstanding shares have now reached $82.73 million.
The firm has a total of 246 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.3%, operating margin of -777.25%, and the pretax margin is -733.74%.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.91%, while institutional ownership is 62.52%. The most recent insider transaction that took place on Mar 04 ’25, was worth 7,030. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 4,109 shares at a rate of $1.71, taking the stock ownership to the 112,720 shares. Before that another transaction happened on Mar 04 ’25, when Company’s CEO sold 16,632 for $1.71, making the entire transaction worth $28,452. This insider now owns 295,474 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.10% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Analysing the last 5-days average volume posted by the [Editas Medicine Inc, EDIT], we can find that recorded value of 4.22 million was lower than the volume posted last year of 4.54 million. As of the previous 9 days, the stock’s Stochastic %D was 12.15%. Additionally, its Average True Range was 0.29.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 16.42%, which indicates a significant increase from 2.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 339.49% in the past 14 days, which was higher than the 156.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4820, while its 200-day Moving Average is $3.2640. Now, the first resistance to watch is $1.6600. This is followed by the second major resistance level at $1.7600. The third major resistance level sits at $1.8300. If the price goes on to break the first support level at $1.4900, it is likely to go to the next support level at $1.4200. Now, if the price goes above the second support level, the third support stands at $1.3200.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 82,976K shares outstanding in the company with a market cap of 129.44 million. Presently, the company’s annual sales total 78,120 K according to its annual income of -153,220 K. Last quarter, the company’s sales amounted to 60 K and its income totaled -62,140 K.
